MAB393
antibody from Novus Biologicals
Targeting: PPBP
b-TG1, Beta-TG, CTAP3, CTAPIII, CXCL7, LA-PF4, LDGF, MDGF, NAP-2, NAP-2-L1, PBP, SCYB7, TGB, TGB1, THBGB1
Antibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [1]
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB393 - Provider product page
- Provider
- Novus Biologicals
- Product name
- Mouse Monoclonal CXCL7/NAP-2 Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from hybridoma culture supernatant. Detects human CXCL7/NAP-2 in ELISAs and Western blots. In sandwich ELISAs, less than 0.05% cross-reactivity with recombinant human (rh) CXCL1, 2, 3, 5, 6, 8, 9, 10, or 12 is observed. In Western blots, no cross-reactivity with rhCXCL1, 2, 3, 5, 6, 8, 9, 10, 12, 13, recombinant mouse CXCL1, 2, 6, 9, 10, 12 or recombinant rat CXCL1, 2 or 3 is observed.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 500 ug
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
Submitted references Development of a Glycosaminoglycan Derived, Selectin Targeting Anti-Adhesive Coating to Treat Endothelial Cell Dysfunction.
Effect of platelet-derived β-thromboglobulins on coagulation.
Up-regulation of platelet activation in hemophilia A.
High platelet reactivity is associated with myocardial infarction in premenopausal women: a population-based case-control study.
Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation.
Wodicka JR, Chambers AM, Sangha GS, Goergen CJ, Panitch A
Pharmaceuticals (Basel, Switzerland) 2017 Mar 29;10(2)
Pharmaceuticals (Basel, Switzerland) 2017 Mar 29;10(2)
Effect of platelet-derived β-thromboglobulins on coagulation.
Egan K, van Geffen JP, Ma H, Kevane B, Lennon A, Allen S, Neary E, Parsons M, Maguire P, Wynne K, O' Kennedy R, Heemskerk JWM, Áinle FN
Thrombosis research 2017 Jun;154:7-15
Thrombosis research 2017 Jun;154:7-15
Up-regulation of platelet activation in hemophilia A.
van Bladel ER, Roest M, de Groot PG, Schutgens RE
Haematologica 2011 Jun;96(6):888-95
Haematologica 2011 Jun;96(6):888-95
High platelet reactivity is associated with myocardial infarction in premenopausal women: a population-based case-control study.
Snoep JD, Roest M, Barendrecht AD, De Groot PG, Rosendaal FR, Van Der Bom JG
Journal of thrombosis and haemostasis : JTH 2010 May;8(5):906-13
Journal of thrombosis and haemostasis : JTH 2010 May;8(5):906-13
Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation.
Smith C, Damås JK, Otterdal K, Øie E, Sandberg WJ, Yndestad A, Waehre T, Scholz H, Endresen K, Olofsson PS, Halvorsen B, Gullestad L, Frøland SS, Hansson GK, Aukrust P
Journal of the American College of Cardiology 2006 Oct 17;48(8):1591-9
Journal of the American College of Cardiology 2006 Oct 17;48(8):1591-9
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Detection of Human CXCL7/NAP-2 by Simple WesternTM. Simple Western lane view shows lysates of human platelets, loaded at 0.2 mg/mL. A specific band was detected for CXCL7/NAP-2 at approximately 10 kDa (as indicated) using 10 µg/mL of Mouse Anti-Human CXCL7/NAP-2 Monoclonal Antibody (Catalog # MAB393) . This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Myeloperoxidase Release Induced by CXCL7/NAP-2 and Neutralization by Human CXCL7/NAP-2 Antibody. Recombinant Human CXCL7/NAP-2 (Catalog # 393-NP) induces myeloperox-idase release in the cytochalasin-B treated human neutrophils in a dose-dependent manner (orange line). Myeloperoxidase Release elicited by Recombinant Human CXCL7/NAP-2 (1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CXCL7/ NAP-2 Monoclonal Antibody (Catalog # MAB393). The ND50 is typically 15-20 µg/mL in the presence of cytochalasin-B.